Publication Name	World Journal of Clinical Oncology
Manuscript ID	8264
Country	Canada

Received	2014-01-13 08:57
Peer-Review Started	2014-02-08 11:47
First Decision by Editorial Office Director
Return for Revision	2014-04-21 16:07
Revised	2014-04-30 02:10
Publication Fee Transferred
Second Decision by Editor	2014-07-14 17:02
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2014-07-14 17:24
Articles in Press	2014-07-14 17:27
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-19 11:03
Publish the Manuscript Online	2014-12-11 14:23

ISSN	2218-4333 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Competing risks of death in younger and older postmenopausal breast cancer patients
Manuscript Source	Invited Manuscript
All Author List	Judy-Anne W Chapman, Kathleen I Pritchard, Paul E Goss, James N Ingle, Hyman B Muss, Susan F Dent, Ted A Vandenberg, Brian Findlay, Karen A Gelmon, Carolyn F Wilson, Lois E Shepherd and Michael N Pollak
Funding Agency and Grant Number	Funding Agency Grant Number Canadian Cancer Society through a grant to the NCIC Clinical Trials Group from the Canadian Cancer Society Research Institute Novartis provided the NCIC CTG MA.14 drug octreotide LAR
Corresponding Author	Judy-Anne W Chapman, PhD, Senior Biostatistician, NCIC Clinical Trials Group, Queen's University, 10 Stuart Street, Kingston, ON, K7L 3N6, Canada. jchapman@ctg.queensu.ca
Key Words	Breast cancer; Postmenopausal; Hormone receptor positive; Competing risks; Tamoxifen; Octreotide LAR
Core Tip	With earlier detection and improved therapies, patients with early breast cancer simultaneously face multiple health risks; 54% of women ≥ 70 years at diagnosis died from other causes. Octreotide LAR, an early drug targeting the insulin pathway, might have affected both breast and other cause mortality. We demonstrated a method of jointly assessing the impact of therapy and baseline patient characteristics on multiple causes of death. Older patients with higher body mass index experienced more other cause mortality, while women with smaller hormone receptor positive tumours and less lymph node involvement were less likely to die from breast cancer.
Publish Date	2014-12-11 14:23
Citation	Chapman JAW, Pritchard KI, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN. Competing risks of death in younger and older postmenopausal breast cancer patients. World J Clin Oncol 2014; 5(5): 1088-1096
URL	http://www.wjgnet.com/2218-4333/full/v5/i5/1088.htm
DOI	http://dx.doi.org/10.5306/wjco.v5.i5.1088

Full Article (PDF)	WJCO-5-1088.pdf
Full Article (Word)	WJCO-5-1088.doc
Manuscript File	8264-Review.doc
Answering Reviewers	8264-Answering reviewers.pdf
Copyright License Agreement	8264-Copyright assignment.pdf
Peer-review Report	8264-Peer review(s).pdf
Scientific Misconduct Check	8264-CrossCheck.jpg
Scientific Editor Work List	8264-Scientific editor work list.pdf